_edited.png)
RISK CONCERN
Investment Strategy, Risk Analysis, and Insights by Chartered Professionals
UFPT
Primary Facts
Medical Devices
Name:
-
Sector:
- 5550.00K
Industry:
92.26
CEO:
Mr. R. Jeffrey Bailly
Total Employees:
Small Cap
Our Technological Advancement Rating
Our Rating:
1.138681544
4.851311308
Ufp Technologies, Inc. (XNAS:UFPT) In-Depth Stock/Fundamental/Options Analysis Today
Primary Targets/Price Insights
Previous Close ($) :
UFP TECHNOLOGIES, INC. (XNAS:UFPT)
One Month Price Target:
Six Month Price Target :
$92.62
Likely Price in One Year's Time:
Ticker:
$94.44
Likely Trading Range Today Under (Normal Volatility)
$92.8
Price Upper limit ($) :
$96.63
Price Lower limit ($) :
Crash Risk Prep/Key Price Levels (High Volatility/Risk)
Price, as per data analysis, isn't likely to fall below:
Today:
P129
This week:
$87.4
This month :
$81.4
Other Primary facts
Market Cap:
7.57M
Market Cap Classification:
691.43M
Number of Shares
IPO Date:
B
Best/Worst Daily Performance (Last 3+ Years)
Highest Daily Appreciation:
-16.65%
$70.53
Worst Daily Decline:
Our Options Trading Entry Points
Iron Condor entry points for options expiring in 1 week's time
Low risk (<2%) entry points
Buy Call:
Sell Call:
Buy Put:
Sell Put:
$104.26
14.63%
$80.26
$114.78
Medium risk (<10%) entry points
Buy Call
Sell Call
$98.59
Buy Put:
Sell Put:
$69.74
$85.93
$100.83
These entry points can be used for other strategies, such as butterflies, straddles, etc.
Risk-Adjusted returns (Sharpe Ratio) of
Medical Devices
Sharpe Ratio:
UFPT, is amongst the top 20% highest yielding stocks in terms of daily returns
Comparison:
1.51%
2.177916662
Sharpe ratio is 217.79% higher than the industry
Average Returns/Yield of
Medical Devices
Daily returns:
1
Weekly returns:
0.14%
Monthly returns:
0.68%
Yearly returns:
32.51%
Comparison of returns:
1.116739007
Classification:
Average annual returns/yield (last 3 years) is 111.67% above industry average
Results of T-Test of Returns:
UFPT is a riskier investment compared to Nasdaq (IXIC)
Statistical test of Returns:
0.41
Volatility (measured by Standard Deviation)
Daily Volatility:
& ratio is 111.18% higher than the market/S&P 500 average
Weekly Volatility:
2.63%
Monthly Volatility:
5.88%
Yearly Volatility:
11.76%
Volitlilty of last five days (Measured by Standard Deviation)
Average Volatility of this Week:
51.27%
-46.28%
Value at Risk Analysis (VaR)
Daily VaR:
Volatility in last five trading days has been -46.28% below long-term volatility
Weekly VaR:
-5.27%
Monthly VaR:
-11.78%
How Much Can the price of
Medical Devices
Decline in a Recession?
Likely price decline in a recession:
Base case (decline):
Risk of crash in next 6/12 months: Very high (>70%)
Worst case (decline):
$74.48
This translates to price declining to:
-19%
This translates to price declining to:
-81.58%
Severe Crash Probability
-23.55%
What is Value at Risk (VaR)?
Risk Fundamentals
42.40%
UFPT is a 66.22% riskier investment compared to the market/S&P 500 & is 42.40% riskier than Nasdaq (IXIC)
UFPT is a 66.22% riskier investment compared to the market/S&P 500
Beta Examination of
Medical Devices
0.705
Expected beta in 1 year's time:
0.6
Expected beta in 3 year's time:
0.553
Unlevered (debt free) Beta:
Beta in relation to market/S&P 500--0.70
Beta in relation to Nasdaq (XNAS):
Returns are, approximately, symmetrical
Beta in relation to all global stocks::
Beta is -33.84% below industry average
Beta Comparison & Analysis
Beta of competitors/peers::
0.514
-0.521
Average Industry Beta:
Beta is -52.08% lower than peers
-0.338386196
Sustainable Growth Rate Analysis
Sustainable growth rate for this stock/firm:
WACC is -25.46% below industry mean WACC
-29.62%
Alpha provided | Alpha Analysis
Alpha provided:
0.783
3.993
15.616
Analysis of Cost of Capital of
Medical Devices
Equity cost of capital:
Alpha is 1562% higher than market/& is unsustainably high
-0.236
Unlevered (without debt) cost of capital:
Equity cost of capital is -23.63% below industry mean WACC
Before-tax cost of debt:
5.82%
After-tax cost of debt:
0.42%
Overall debt rating:
0.33%
Weighted average cost of capital (WACC):
0.42%
-25.46%
Key Per-Share Metrics & Analysis
Revenue per share:
-
Revenue growth rate per share of (3Y):
Price to sales ratio is -67.25% below the industry mean
-98.30%
EPS:
Sixteen Million Four Hundred Eighty-Two Thousand Nine Hundred Eighty Dollars
Expected Annual growth rate of EPS (3Y):
-
-166.70%
Free cash flow (FCF) per share:
Price to book ratio is -59.10% below the industry mean
-
-
Debt per share
Debt repayment rate in last quarter: 7.56%
EBITDA per share
Each employee generates 178% more EBITDA than industry average revenue per employee
Valuation Analysis Today of
Medical Devices
P/E Ratio:
Sustainable growth rate is -29.62% below industry average
P/E Ratio of Competitors/Peers:
33.83
-0.861078107
530.929161
-0.826229172
$0.19
-
P/S (Price to Sales ratio):
$30.26
-0.672459968
P/B (Price to book value ratio):
Price to sales ratio is -67.25% below the industry mean
-
-
Net income growth rate (3Y):
Annual revenue growth rate is -98.30% below industry average
-90.76%
Dividend Analysis
Net income growth rate is -90.76% lower than the industry average net income growth rate
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Dividend History:
-
--$0.00
--$0.00
--$0.00
--$0.00
--$0.00
-
In-depth Debt & Leverage Analysis
Debt to equity ratio:
50.43%
Net debt to equity ratio:
The remaining useful life of property plant & equipment is: 5.9 years
Debt to assets ratio:
27.63%
Net debt to assets ratio:
49.22%
-30.39%
Ability to repay debt:
Interest coverage ratio:
Debt-to-asset ratio is -30.39% below industry average
4.52
Looking forward:
Debt growth rate:
1.4x
1439.55%
7.56%
Analysis of Key Statistics
Correlation of price movement with the market:
9.070076666
Statistical significance of correlation:
-0.31%
Average Correlation of the industry with the market:
0.328
-29.93%
R Squared (percentage of price movement explained by movement of the market):
0.328
Correlation of price movement with Nasdaq (^IXIC):
0.107
Covariance of price movement with the market:
0.033
Kurtosis
0.051
5.709
Skewness of returns:
Returns have moderate fat-tails (leptokurtic), i.e., returns considerably higher or lower than the mean returns are more probable, compared to assets with normally distributed returns
0.123
Fundamental Analysis & Dupont Analysis of
Medical Devices
Gross Profit Margin Ratio:
55.64M
Operating Profit Margin Ratio:
Net profit margin is -142.41% lower than the industry
-156.99%
Net Profit Margin Ratio:
55.64M
Effective Tax Rate:
4.17%
-0.551781084
Dupont Method
Net Profit Margin
Return on Equity Ratio (ROE):
×
ROA
=
×
Return on assets (ROA) is -235.36% lower than the industry
-184.95%
Financial Leverage
Asset Turnover Ratio (ROA):
Operating profit margin is -156.99% lower than the industry
-235.36%
Financial Leverage:
Interest coverage ratio is 451.58% more than industry average
Current Ratio:
Return on equity (ROE) is -184.95% lower than the industry
-0.607787338
Cash Conversion Cycle (days):
$12.95
0.016837142
Current ratio is -60.78% below industry average
Stock based compensation to net income ratio:
-
In-depth Efficiency Analysis
Revenue generated per employee:
Cash conversion cycle is 1.68% above industry average
-0.667663452
EBITDA generated per employee:
Each employee generates -67% less revenue than industry average revenue per employee
1.779411463
Profit generated per employee:
$4.20
-131%
Free cash flow (FCF) generated per employee:
Each employee generates -131% less net income/profit than industry average revenue per employee
-0.786252821
Assets/Capital per employee
Each employee generates -79% less free cash flow than industry average revenue per employee
-0.786252821
Research & Development (R&D) Analysis
-
-
Competitors/Peer firms of
Medical Devices
$100.40
DEL TACO RESTAURANTS, INC. (XNAS:TACO)
ELECTRAMECCANICA VEHICLES CORP. (XNAS:SOLO)
VOXX INTERNATIONAL CORPORATION (XNAS:VOXX)
TRAVELCENTERS OF AMERICA INC. (XNAS:TA)
KANDI TECHNOLOGIES GROUP, INC. (XNAS:KNDI)
YUNJI INC. (XNAS:YJ)
AMERICAN OUTDOOR BRANDS, INC. (XNAS:AOUT)
COMMERCIAL VEHICLE GROUP, INC. (XNAS:CVGI)
Current Analyst Ratings
$2.18
Strong buy�4%
Buy�0%
Hold�0%
Sell�0%
Strong sell�0%
Income Statement
Period:
3/31/2022
Date:
Value
Revenue:
TTM
Cost of Revenue:
Gross Profit:
R&D Expense
General & Admin Expenses:
Selling, General & Admin Expenses
Sales and Marketing Expenses
Other Expenses :
Operating Expenses :
Cost & Expenses :
Interest Income:
Interest Expenses:
Depreciation & Amortization:
EBITDA:
Operating Income:
Other Income Expenses:
Income Before Tax:
Income Tax Expense:
Net Income:
Balance Sheet
Date:
Calendar Year:
Period:
Cash & Cash Equivalents:
Short Term Investments:
Cash & Short Term Investments:
Net Receivables:
Inventory:
Other Current Assets:
Total Current Assets:
PP&E:
Goodwill:
Intangible Assets:
Long Term Investments:
Tax Assets:
Other Non-Current Assets:
Total Non-Current Assets:
Other Assets:
Total Assets:
Accounts Payable:
Short Term Debt:
Tax Payables:
Deferred Revenue:
Other Current Liabilities:
Total Current Liabilities:
Long Term Debt:
Other Non-Current Liabilities:
Total Non Current Liabilities:
Other Liabilities:
Total Liabilities:
Common Stock:
Retained Earnings:
Accumulated Other Comprehensive Loss:
Other Total Stockholders' Equity:
Total Stockholders' Equity:
Total Liabilities and Stockholders' Equity:
Total Investments:
Total Debt:
Net Debt:
228.96M
173.32M
97%
-
-
32.18M
-
-
205.51M
61.00K
432.00K
9.36M
56%
5.42M
- 282.00K
39%
5.42M
Statement of Cash Flow
Date:
Period:
4.86M
Differed Income Tax :
3.02M
Stock Based Compensation :
- 440.00K
Change in Working Capital :
692.00K
Accounts Receivables:
- 11331.00K
Other Working Capital:
4.11M
Other Non-Cash Items:
497.00K
Net Cash Provided by Operating Activities:
- 11.00K
Investments in PP&E:
- 3216.00K
Net Acquisitions:
- 2334.00K
Purchases of Investments:
- 20653.00K
Sales/Maturities of Investments:
Other Investing Activities:
Net Cash Used for Investing Activities:
Debt Repayment:
Common Stock Issued:
Common Stock Repurchased:
Dividend Paid:
Other Financing Activities:
Net Cash Used Provided by Financing Activities:
Effect of FOREX on Changes in Cash:
Net Changes in Cash:
Cash at End of Period:
Cash at Beginning of Period:
Operating Cash Flow:
Capital Expenditure:
Free Cash Flow (FCF):
Value
3/31/2022
2022
Q1
3.65M
-
3.65M
46.18M
43.30M
5.31M
98.44M
72.18M
115.57M
71.57M
-
-
5.59M
264.91M
-
363.35M
15.67M
6.05M
2.11M
5.04M
12.06M
38.82M
97.99M
24.02M
125.44M
-
164.27M
76.00K
165.67M
381.0K
Value
32.18M
32.96M
199.08M
363.35M
-
104.04M
-
-
12.00K
- 22975.00K
- 8016.00K
-
-
-
26.70M
18.69M
41.00K
- 7465.00K
3.65M
11.12M
- 3216.00K
- 2334.00K
Our Proprietary Portfolio Rating
Our Rating:
70.93240675
Price Forecast/Expected Price in Next 5 Years of
Medical Devices
2023
2024
2025
2026
2027
83.44074939
$83.44
$87.39
$91.53
$95.86